These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
400 related articles for article (PubMed ID: 27885469)
1. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Aapro M; Karthaus M; Schwartzberg L; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Hansen V; Rossi G; Rizzi G; Borroni ME; Rugo H Support Care Cancer; 2017 Apr; 25(4):1127-1135. PubMed ID: 27885469 [TBL] [Abstract][Full Text] [Related]
2. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Aapro M; Rugo H; Rossi G; Rizzi G; Borroni ME; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Lorusso V; Karthaus M; Schwartzberg L; Grunberg S Ann Oncol; 2014 Jul; 25(7):1328-1333. PubMed ID: 24603643 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials. Rugo HS; Rossi G; Rizzi G; Aapro M Breast; 2017 Jun; 33():76-82. PubMed ID: 28285236 [TBL] [Abstract][Full Text] [Related]
4. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Gralla RJ; Bosnjak SM; Hontsa A; Balser C; Rizzi G; Rossi G; Borroni ME; Jordan K Ann Oncol; 2014 Jul; 25(7):1333-1339. PubMed ID: 24631949 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Hesketh PJ; Rossi G; Rizzi G; Palmas M; Alyasova A; Bondarenko I; Lisyanskaya A; Gralla RJ Ann Oncol; 2014 Jul; 25(7):1340-1346. PubMed ID: 24608196 [TBL] [Abstract][Full Text] [Related]
6. Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studies. Schwartzberg L; Karthaus M; Rossi G; Rizzi G; Borroni ME; Rugo HS; Jordan K; Hansen V Cancer Med; 2019 May; 8(5):2064-2073. PubMed ID: 30968588 [TBL] [Abstract][Full Text] [Related]
7. Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. Caputo R; Cazzaniga ME; Sbrana A; Torrisi R; Paris I; Giordano M; Montesarchio V; Guarneri V; Amaducci L; Bilancia D; Cilenti G; Fabi A; Collovà E; Schirone A; Bonizzoni E; Celio L; De Placido S; De Laurentiis M BMC Cancer; 2020 Mar; 20(1):232. PubMed ID: 32188417 [TBL] [Abstract][Full Text] [Related]
8. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012 [TBL] [Abstract][Full Text] [Related]
9. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting. Shirley M Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy. Bošnjak SM; Stamatovic L; Borroni ME; Rizzi G; Jordan K Int J Gynecol Cancer; 2018 Jul; 28(6):1153-1161. PubMed ID: 29794499 [TBL] [Abstract][Full Text] [Related]
11. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. Schwartzberg L; Navari R; Clark-Snow R; Arkania E; Radyukova I; Patel K; Voisin D; Rizzi G; Wickham R; Gralla RJ; Aapro M; Roeland E Oncologist; 2020 Mar; 25(3):e589-e597. PubMed ID: 32162813 [TBL] [Abstract][Full Text] [Related]
12. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Navari RM Drug Des Devel Ther; 2015; 9():155-61. PubMed ID: 25552904 [TBL] [Abstract][Full Text] [Related]
13. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy. Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study. Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742 [TBL] [Abstract][Full Text] [Related]
15. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Navari RM; Binder G; Bonizzoni E; Clark-Snow R; Olivari S; Roeland EJ Future Oncol; 2021 Aug; 17(23):3027-3035. PubMed ID: 33878896 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients. Aapro M; Jordan K; Gralla RJ; Rizzi G; Rossi G; Palmas M; Alyasova AV; Lisyanskaya AS; Bošnjak SM; Hesketh PJ J Geriatr Oncol; 2017 Jan; 8(1):56-63. PubMed ID: 27889278 [TBL] [Abstract][Full Text] [Related]
17. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Schwartzberg L; Roeland E; Andric Z; Kowalski D; Radic J; Voisin D; Rizzi G; Navari R; Gralla RJ; Karthaus M Ann Oncol; 2018 Jul; 29(7):1535-1540. PubMed ID: 29722791 [TBL] [Abstract][Full Text] [Related]
18. Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. Jordan K; Gralla R; Rizzi G; Kashef K Support Care Cancer; 2016 Nov; 24(11):4617-25. PubMed ID: 27334131 [TBL] [Abstract][Full Text] [Related]
19. Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting. Lorusso V; Karthaus M; Aapro M Future Oncol; 2015; 11(4):565-77. PubMed ID: 25360998 [TBL] [Abstract][Full Text] [Related]
20. Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV). Baron-Hay S; Aapro M; Bernareggi A; Schwartzberg L Support Care Cancer; 2019 Apr; 27(4):1309-1317. PubMed ID: 30685793 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]